What the FDA labels say about taking them together
Dipyridamole and riociguat
Riociguat's FDA label of August 13, 2026 names dipyridamole in its contraindications section; the dipyridamole label PlainMeds reads does not name riociguat. The riociguat label: “Concomitant administration of Adempas with specific PDE-5 inhibitors or nonspecific PDE-5 inhibitors is contraindicated.”
Check it at the source: the dipyridamole FDA label on DailyMed (effective September 16, 2023, Zydus Pharmaceuticals USA Inc.); the riociguat FDA label on DailyMed (effective August 13, 2026, Bayer HealthCare Pharmaceuticals Inc.).
What does the dipyridamole label say about riociguat?
Dipyridamole's label (effective September 16, 2023) does not name riociguat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dipyridamole), Zydus Pharmaceuticals USA Inc., effective September 16, 2023 (SPL set 004bada0-dbf7-4a94-8792-6833d7eeda2b), via openFDA; the full label on DailyMed
What does the riociguat label say about dipyridamole?
Riociguat label, contraindicationsConcomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )].
Riociguat label, drug interactionsPDE Inhibitors: Co-administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension.
Source: FDA drug label (Adempas), Bayer HealthCare Pharmaceuticals Inc., effective August 13, 2026 (SPL set 7b57509a-3d5d-41d4-8fed-1471e26372a3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dipyridamole | Riociguat | |
|---|---|---|
| Labeled for | n/a | Pulmonary arterial hypertension |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.236 per tablet 75 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once